Evidence map›Paper›PMID 37129030›Full record

ReviewInternational journal of technology assessment in health care2023

Expanding health technology assessment towards broader value: Ireland as a case study.

Irina Kinchin, Valerie Walshe, Charles Normand, Joanna Coast, Rachel Elliott, Thilo Kroll, Philip Kinghorn, Alexander Thompson, Rosalie Viney, David Currow and 1 more

Abstract readReview
In one paragraph

Review in International journal of technology assessment in health care, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Getting fairer over time? Assessing changes in health technology funding processes using the accountability for reasonableness (A4R) framework.The European journal of health economics : HEPAC : health economics in prevention and care · 2026
    Article
  3. Review
  4. Assessing medical devices: a qualitative study from the validate perspective.International journal of technology assessment in health care · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Irina KinchinCentre for Health Policy and Management, Trinity College Dublin, The University of Dublin, Dublin, Ireland.ORCID https://orcid.org/0000-0003-0133-2763
Valerie WalsheHealth Service Executive, Dublin, Ireland.
Charles NormandCentre for Health Policy and Management, Trinity College Dublin, The University of Dublin, Dublin, Ireland.
Joanna CoastBristol Population Health Science Institute, University of Bristol, Bristol, UK.
Rachel ElliottManchester Centre for Health Economics, The University of Manchester, Manchester, UK.
Thilo KrollSchool of Nursing, Midwifery and Health Systems, University College Dublin, Dublin, Ireland.
Philip KinghornHealth Economics Unit, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
Alexander ThompsonManchester Centre for Health Economics, The University of Manchester, Manchester, UK.ORCID https://orcid.org/0000-0003-4930-5107
Rosalie VineyCentre for Health Economics Research and Evaluation (CHERE), University of Technology Sydney, Ultimo, NSW, Australia.
David CurrowFaculty of Science, Medicine and Health, University of Wollongong, Wollongong, NSW, Australia.
James F O'MahonyCentre for Health Policy and Management, Trinity College Dublin, The University of Dublin, Dublin, Ireland.

Funding

Health Research Board ARPP-2020-011
6 · The paper itself

Abstract

Healthcare innovations often represent important improvements in population welfare, but at what cost, and to whom? Health technology assessment (HTA) is a multidisciplinary process to inform resource allocation. HTA is conventionally anchored on health maximization as the only relevant output of health services. If we accept the proposition that health technologies can generate value outside the healthcare system, resource allocation decisions could be suboptimal from a societal perspective. Incorporating "broader value" in HTA as derived from social values and patient experience could provide a richer evaluative space for informing resource allocation decisions. This article considers how HTA is practiced and what its current context implies for adopting "broader value" to evaluating health technologies. Methodological challenges are highlighted, as is a future research agenda. Ireland serves as an example of a healthcare system that both has an explicit role for HTA and is evolving under a current program of reform to offer universal, single-tier access to public services. There are various ways in which HTA processes could move beyond health, including considering the processes of care delivery and/or expanding the evaluative space to some broader concept of well-being. Methods to facilitate the latter exist, but their adaptation to HTA is still emerging. We recommend a multi-stakeholder working group to develop and advance an international agenda for HTA that captures welfare/benefit

Indexed as

Delivery of Health CareTechnology Assessment, BiomedicalBiomedical TechnologyHumansIrelandResource Allocationbenefits beyond healthHealth technology assessment (HTA)outcome measurementresource allocationsocial valuewellbeing

Identifiers

PMID37129030
PMCPMC11569971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.